< Zurück zu den aktuellen Neuigkeiten & Events

UPC

Unitary Patent Renewal Fees – proposed figures revealed

März 2015

Ever since the prospect of a Unitary Patent for Europe became a reality, the subject of cost has been hotly debated. Will a Unitary Patent save me money? But with so many unknowns, the question has been like a puzzle.

According to various sources, we could have the first piece in the puzzle, with the EPO having made a proposal on the level of renewal fees. In a document “Proposals for the level of renewal fees for European patents with unitary effect”, (which we’ve yet to see a copy of) submitted by the President of the EPO to the Select Committee of the Administrative Council for their opinion, the EPO has come up with the following proposal:

To meet the requirements set out in Article 12 of the Regulation on the Unitary Patent, the EPO has allegedly proposed the following structure for setting unitary patent renewal fees:

  • years 3 to 5: the level of the EPO’s internal renewal fees (IRF) [these are the fees payable to the EPO for pending patent applications currently]
  • years 6 to 9: a transitional level between the IRF level and the year 10 level
  • from year 10, a level equivalent to the total sum of the national renewal fees payable in the states in
    which European patents are most frequently validated (TOP level)

Furthermore, based on this, two specific proposals are made – one where the Year 10 onwards level is based on current renewal fee levels for FOUR European countries (TOP 4 level) and one where the Year 10 onwards level is based on current renewal fee levels for FIVE European countries (TOP 5 level) but with a reduction for certain categories of patentees, namely SMEs, natural persons, non-profit organisations, universities and public research
organisations.

Based on these proposals, the cost of obtaining a UP would be more expensive than current filing strategies, if for example patentees usually validate in 3 or less states. And of course, given that it will not be possible to be selective as to EP countries which are maintained throughout the life of the patent, there is no option to scale down costs towards the end of the patent term.

We still need more pieces in the puzzle to get the full picture on whether a UP will save money in the long run.

Aktuelle Neuigkeiten

UK IPO fees to increase from 1 April 2026

Whilst the fee changes are subject to parliamentary approval, they are almost certain to take effect – read on to learn more. The United Kingdom Intellectual Property Office (UK IPO) …

Weiterlesen

Mycelium Meets Market Reality: The Quiet Role of IP in Scaling Sustainable Materials

Fungal materials are increasingly used in applications ranging from sustainable packaging and leather alternatives to construction composites, textiles, and biotechnology. These developments are transforming fungi from a niche research subject …

Weiterlesen
Event - 24. bis 25. November 2025

HGF Partners with 3AF for the P2I2025 Symposium

HGF are pleased to be a partner of P2I2025, the annual symposium organised by the Intellectual Property Commission of the French Aeronautics and Astronautics Association (3AF). The event brings together …

Veranstaltungsdetails

Retailers liability and AI Applications

The question of whether the user (consumer) or the provider of an AI application is liable for the infringement of intellectual property rights as a result of the use of …

Weiterlesen
Event - 11. November 2025

OIS Investor Forum - Jeffries

HGF is proud to be sponsoring the OIS Investor Forum on 18th November. One of the premier gatherings for leaders, innovators, and investors across the healthcare industry. The forum covers …

Veranstaltungsdetails

From Stripes to Supermarkets: The Court of Appeal Reaffirms the Need for Precision in Trade Mark Law

On 23 October 2025, Lord Justice Arnold delivered two landmark Court of Appeal decisions addressing trade mark registrability: Thom Browne Inc & Anor v adidas AG [2025] EWCA Civ 1340 …

Weiterlesen

Protecting Digital Health innovation in the AI revolution

As artificial intelligence (AI) continues to transform healthcare, from diagnostic imaging and drug discovery to wearable devices and clinical decision support, questions around how to protect these advancements have become …

Weiterlesen

Doubling Up on Added Matter at the UPC

Following the UPC Court of Appeal (CoA) decision in Abbott v Sibio (APL_39664/2024, 14 February 2025) we now have a second CoA decision on added matter in expert Klein v …

Weiterlesen